ArticlePediatric nephrology (Berlin, Germany)2026
Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Anti-rituximab antibodies: implications for clinical outcomes and safety in pediatric idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Re-treatment with rituximab for steroid-dependent nephrotic syndrome in patients with anti-rituximab antibodies.Pediatric nephrology (Berlin, Germany) · 2026Article
- Response to: "Re-treatment with rituximab for steroid-dependent nephrotic syndrome in patients with anti-rituximab antibodies".Pediatric nephrology (Berlin, Germany) · 2026Article
- Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundB-cell-depleting agents like rituximab (RTX) are central to treating severe steroid-dependent idiopathic nephrotic syndrome (SDNS) and frequent relapses. However, RTX can induce anti-RTX antibodies (ARA) that compromise efficacy. Obinutuzumab, a fully humanized anti-CD20 antibody, may overcome RTX resistance. We evaluate obinutuzumab's safety and efficacy in pediatric SDNS patients who developed ARA after RTX.
methodsWe conducted a retrospective study in two pediatric nephrology centers in Paris, France, including SDNS patients treated with RTX who developed ARA and subsequently received obinutuzumab.
resultsThirty-two patients (median age 4.1 years) were included, previously treated with a median of 2 RTX infusions (IQR 1-2). ARA were detected at 3.2 months (range 0-17), following a median depletion of 2.9 months (IQR 2.1-5.8); 13/32 had titers ≥ 100 ng/mL. Obinutuzumab was given for short/failed RTX depletion (n = 19) or early relapse (n = 13). Six infusion reactions occurred but no serum sickness. B-cell depletion after obinutuzumab lasted 6.5 months (IQR 5.6-8.1). Among 28 patients with baseline ARA at obinutuzumab infusion, 50% had titers ≥ 100 ng/mL, with no difference in B-cell depletion (median 5.3 vs. 6.8 months; p = 0.40), or relapse-free survival at 24 months (75% vs. 46%; p = 0.10). Longitudinal ARA monitoring showed sustained positivity in 76.5% at 6 months, and one patient > 100 ng/mL at 24 months.
conclusionObinutuzumab is an effective and well-tolerated option in the context of ARA, providing prolonged B-cell depletion. Further studies with ARA monitoring are needed to optimize anti-CD20 therapy.
Indexed as
Identifiers
41238968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.